Morgan Stanley Regulus Therapeutics Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 27,819 shares of RGLS stock, worth $63,705. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,819

Holding current value

$63,705

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 15, 2024	BUY	$1.13 - $2.88 $31,435 - $80,118	27,819 New	27,819 $80,000
Q4 2022 Feb 14, 2023	BUY	$1.17 - $1.85 $17 - $27	15 New	15 $0

Others Institutions Holding RGLS

# of Institutions

Shares Held

36.4M

Call Options Held

239K

Put Options Held

12.6K

Federated Hermes, Inc. Pittsburgh, PA

12.9M
Shares

$29.4 Million
0.09% of portfolio
Vivo Capital, LLC Palo Alto, CA

5M
Shares

$11.5 Million
1.93% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.68M
Shares

$8.43 Million
0.02% of portfolio
Deep Track Capital, LP Greenwich, CT

3.27M
Shares

$7.48 Million
0.31% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.88M
Shares

$4.29 Million
0.0% of portfolio

View Full List

About Regulus Therapeutics Inc.

Ticker RGLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,634,400
Market Cap $33.5M
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...

More about RGLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account